Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NPCE NeuroPace Inc
- Stocks
- Healthcare
- NASDAQ: NPCE
Price (delayed)
$17.68
Market cap
$579.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.83
Enterprise value
$625.89M
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating
Highlights
NPCE's equity has surged by 69% year-on-year
NeuroPace's EPS has increased by 30% YoY and by 11% QoQ
Key stats
What are the main financial stats of NPCE
Market
Valuations
Earnings
Shares outstanding
32.8M
Market cap
$579.88M
Enterprise value
$625.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
23.72
Price to sales (P/S)
6.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.42
Revenue
$84.31M
Gross profit
$63.08M
Operating income
-$19.27M
Net income
-$24.81M
EBIT
-$16.11M
EBITDA
-$14.3M
Free cash flow
-$18.14M
Per share
Balance sheet
Liquidity
EPS
-$0.83
EPS diluted
-$0.83
Free cash flow per share
-$0.58
Book value per share
$0.75
Revenue per share
$2.68
TBVPS
$3.5
Total assets
$110.21M
Total liabilities
$85.94M
Debt
$73.15M
Equity
$24.27M
Working capital
$82.77M
Debt to equity
3.01
Current ratio
6.63
Quick ratio
5.56
Net debt/EBITDA
-3.22
Margins
Efficiency
Dividend
EBITDA margin
-17%
Gross margin
74.8%
Net margin
-29.4%
Operating margin
-22.9%
Return on assets
-25.1%
Return on equity
-190.8%
Return on invested capital
-11.5%
Return on capital employed
-16.9%
Return on sales
-19.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NPCE stock price
How has the NeuroPace stock price performed over time
Intraday
-1.06%
1 week
1.09%
1 month
62.05%
1 year
132.63%
YTD
58%
QTD
43.86%
Financial performance
How have NeuroPace's revenue and profit performed over time
Revenue
$84.31M
Gross profit
$63.08M
Operating income
-$19.27M
Net income
-$24.81M
Gross margin
74.8%
Net margin
-29.4%
NeuroPace's operating margin has increased by 40% YoY and by 15% from the previous quarter
The net margin has increased by 36% YoY and by 14% from the previous quarter
The operating income has increased by 27% year-on-year and by 11% since the previous quarter
NeuroPace's gross profit has increased by 23% YoY and by 7% from the previous quarter
Price vs fundamentals
How does NPCE's price correlate with its fundamentals
Growth
What is NeuroPace's growth rate over time
Valuation
What is NeuroPace stock price valuation
P/E
N/A
P/B
23.72
P/S
6.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.42
NeuroPace's EPS has increased by 30% YoY and by 11% QoQ
The price to book (P/B) is 101% higher than the 5-year quarterly average of 11.8 but 6% lower than the last 4 quarters average of 25.2
NPCE's equity has surged by 69% year-on-year
NPCE's price to sales (P/S) is 83% more than its last 4 quarters average of 3.6 and 65% more than its 5-year quarterly average of 4.0
NPCE's revenue is up by 22% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is NeuroPace business performance
NeuroPace's return on sales has increased by 42% YoY and by 17% QoQ
NeuroPace's ROE has increased by 26% from the previous quarter but it has decreased by 10% YoY
NPCE's ROIC is up by 25% year-on-year and by 11% since the previous quarter
The company's return on assets rose by 19% YoY and by 11% QoQ
Dividends
What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NPCE.
Financial health
How did NeuroPace financials performed over time
NPCE's total assets is 28% higher than its total liabilities
NeuroPace's quick ratio has increased by 28% QoQ and by 3.2% YoY
The company's current ratio rose by 23% QoQ and by 3.1% YoY
NPCE's equity has surged by 69% year-on-year
NeuroPace's debt to equity has shrunk by 67% QoQ and by 41% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.